AMGN - Immatics N.V.: An Intriguing Developmental Concern
2024-04-29 08:51:30 ET
Summary
- Immatics N.V., a European T-Cell receptor therapy company, is expected to release clinical data on all four of its candidates in 2024.
- The company's main focus is on developing T-cell receptor therapies for the treatment of solid tumors.
- Immatics has collaborations with Bristol Myers Squibb totaling $4.2 billion in potential milestones.
- A full investment analysis around this intriguing developmental concern follows in the paragraphs below.
Shares of European T-Cell receptor therapy concern Immatics N.V. ( IMTX ) have traded predominantly below their initial trade on the NASDAQ in 2020 due to a dearth of clinical data. That drought will end in 2024 with readouts anticipated on all four clinical candidates, as well as the expected initiation of a pivotal trial for IMA203 in the treatment of second-line melanoma. With a market cap of $1.08 billion, ~60% of which is cash, and collaborations with Bristol Myers Squibb ( BMY ) totaling $4.2 billion in potential milestones, this developmental concern merited a deeper dive. An analysis follows below....
Immatics N.V.: An Intriguing Developmental Concern